At the MAPS 2022 Global Annual Meeting, we sat down with Riad Dirani, Vice President of Global Health Economics and Outcomes Research at Teva Pharmaceuticals, and Omar Dabbous, Vice President of Global Health Economics and Outcomes Research and Real World Evidence at AveXis to chat about the structure and activities of HEOR within Medical Affairs.
MAPS members represent the full range of Medical Affairs professionals, from those leading or working in large organizations, to those tasked with starting a Medical Affairs function at startup or emerging organizations. Here, MAPS speaks with Lobna Salem, Regional Chief Medical officer Developed Markets& Japan Australia and New Zealand at Viatris, about the process of building Medical Affairs from scratch.
At the MAPS 2022 Global Annual Meeting, MAPS sits down to chat with José Borbolla, Global Executive Medical Director at Esai, and Augusto Grinspan, VP Medical Affairs and Head LATAM with Merck KGaA about developments in the practice and direction of Medical Affairs in Latin America. Augusto and José are also co-chairs of the MAPS Latin America Chapter.
One topic of discussion at the MAPS 2022 Global Annual Meeting was the role of Medical Affairs in patient engagement. Specifically, with patients taking more ownership decisions surrounding care, should Medical Affairs be engaging with patients and/or patient communities in a compliant way? To go even further, should Medical Affairs be the entity within the organization that "owns" patient engagement? Here, Marija Geertsen, VP of Medical Affairs at Lundbeck shares her opinion -- and the story of how her opinion changed during the course of the meeting.
As Medical Affairs professionals, it's easy to focus on the tasks that are right in front of us everyday. In this interview with Monica de Abadal, SVP and Head of Medical Affairs, North America we sat down at the MAPS 2022 Global Annual Meeting to take a step back. Here is how Medical Affairs benefits patients and society. Watch the full interview here.
Medical Affairs describes itself as a third strategic pillar in the biopharmaceutical and MedTech industries alongside R&D and Commercial. But is this truly the case or is Medical Affairs' strategic role still aspirational? And if it is in some ways aspirational, what does Medical Affairs need to do in order to truly achieve its position alongside R&D and Commercial? Here, three Medical Affairs leaders discuss these questions and offer their perspective for the future of the function.